Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 18 entries
Sorted by: Best Match Show Resources per page
Design of a prospective, longitudinal cohort of people living with type 1 diabetes exploring factors associated with the residual cardiovascular risk and other diabetes-related complications: The SFDT1 study.

Diabetes & metabolism

Riveline JP, Vergés B, Detournay B, Picard S, Benhamou PY, Bismuth E, Bordier L, Jeandidier N, Joubert M, Roussel R, Sola-Gazagnes A, Bonnefond A, Clavel S, Velayoudom FL, Beltrand J, Hanaire H, Fontaine P, Thivolet C, Servy H, Tubiana S, Lion S, Gautier JF, Larger E, Vicaut E, Sablone L, Fagherazzi G, Cosson E.
PMID: 34813929
Diabetes Metab. 2021 Nov 21;48(3):101306. doi: 10.1016/j.diabet.2021.101306. Epub 2021 Nov 21.

Type 1 diabetes mellitus (T1DM) is associated with a high risk of cardiovascular (CV) complications, even after controlling for traditional CV risk factors. Therefore, determinants of the residual increased CV morbidity and mortality remain to be discovered. This prospective...

Cite
Riveline JP, Vergés B, Detournay B, et al. Design of a prospective, longitudinal cohort of people living with type 1 diabetes exploring factors associated with the residual cardiovascular risk and other diabetes-related complications: The SFDT1 study. Diabetes Metab. 2021;48(3):101306doi: 10.1016/j.diabet.2021.101306.
Riveline, J. P., Vergés, B., Detournay, B., Picard, S., Benhamou, P. Y., Bismuth, E., Bordier, L., Jeandidier, N., Joubert, M., Roussel, R., Sola-Gazagnes, A., Bonnefond, A., Clavel, S., Velayoudom, F. L., Beltrand, J., Hanaire, H., Fontaine, P., Thivolet, C., Servy, H., Tubiana, S., Lion, S., Gautier, J. F., Larger, E., Vicaut, E., Sablone, L., Fagherazzi, G., & Cosson, E. (2021). Design of a prospective, longitudinal cohort of people living with type 1 diabetes exploring factors associated with the residual cardiovascular risk and other diabetes-related complications: The SFDT1 study. Diabetes & metabolism, 48(3), 101306. https://doi.org/10.1016/j.diabet.2021.101306
Riveline, J P, et al. "Design of a prospective, longitudinal cohort of people living with type 1 diabetes exploring factors associated with the residual cardiovascular risk and other diabetes-related complications: The SFDT1 study." Diabetes & metabolism vol. 48,3 (2021): 101306. doi: https://doi.org/10.1016/j.diabet.2021.101306
Riveline JP, Vergés B, Detournay B, Picard S, Benhamou PY, Bismuth E, Bordier L, Jeandidier N, Joubert M, Roussel R, Sola-Gazagnes A, Bonnefond A, Clavel S, Velayoudom FL, Beltrand J, Hanaire H, Fontaine P, Thivolet C, Servy H, Tubiana S, Lion S, Gautier JF, Larger E, Vicaut E, Sablone L, Fagherazzi G, Cosson E. Design of a prospective, longitudinal cohort of people living with type 1 diabetes exploring factors associated with the residual cardiovascular risk and other diabetes-related complications: The SFDT1 study. Diabetes Metab. 2021 Nov 21;48(3):101306. doi: 10.1016/j.diabet.2021.101306. Epub 2021 Nov 21. PMID: 34813929.
Copy Download .nbib Format: NLM
In silico development of new PET radiopharmaceuticals from mTOR inhibitors.

Journal of molecular graphics & modelling

Ferino-Pérez A, Vélayoudom FL, Belia L, Glaude EL, Gaspard S, Jáuregui-Haza UJ.
PMID: 34847519
J Mol Graph Model. 2021 Nov 24;111:108057. doi: 10.1016/j.jmgm.2021.108057. Epub 2021 Nov 24.

Rapamycin (or sirolimus) is a macrolide that has shown to be useful as an immunosuppressant and that was studied in metabolic, neurological, or genetic disorders. Rapamycin is a specific natural inhibitor of the mechanistic target of rapamycin (mTOR) that...

Cite
Ferino-Pérez A, Vélayoudom FL, Belia L, et al. In silico development of new PET radiopharmaceuticals from mTOR inhibitors. J Mol Graph Model. 2021;111:108057doi: 10.1016/j.jmgm.2021.108057.
Ferino-Pérez, A., Vélayoudom, F. L., Belia, L., Glaude, E. L., Gaspard, S., & Jáuregui-Haza, U. J. (2021). In silico development of new PET radiopharmaceuticals from mTOR inhibitors. Journal of molecular graphics & modelling, 111108057. https://doi.org/10.1016/j.jmgm.2021.108057
Ferino-Pérez, Anthuan, et al. "In silico development of new PET radiopharmaceuticals from mTOR inhibitors." Journal of molecular graphics & modelling vol. 111 (2021): 108057. doi: https://doi.org/10.1016/j.jmgm.2021.108057
Ferino-Pérez A, Vélayoudom FL, Belia L, Glaude EL, Gaspard S, Jáuregui-Haza UJ. In silico development of new PET radiopharmaceuticals from mTOR inhibitors. J Mol Graph Model. 2021 Nov 24;111:108057. doi: 10.1016/j.jmgm.2021.108057. Epub 2021 Nov 24. PMID: 34847519.
Copy Download .nbib Format: NLM
In silico development of new PET radiopharmaceuticals from mTOR inhibitors.

Journal of molecular graphics & modelling

Ferino-Pérez A, Vélayoudom FL, Belia L, Glaude EL, Gaspard S, Jáuregui-Haza UJ.
PMID: 34847519
J Mol Graph Model. 2021 Nov 24;111:108057. doi: 10.1016/j.jmgm.2021.108057. Epub 2021 Nov 24.

Rapamycin (or sirolimus) is a macrolide that has shown to be useful as an immunosuppressant and that was studied in metabolic, neurological, or genetic disorders. Rapamycin is a specific natural inhibitor of the mechanistic target of rapamycin (mTOR) that...

Cite
Ferino-Pérez A, Vélayoudom FL, Belia L, et al. In silico development of new PET radiopharmaceuticals from mTOR inhibitors. J Mol Graph Model. 2021;111:108057doi: 10.1016/j.jmgm.2021.108057.
Ferino-Pérez, A., Vélayoudom, F. L., Belia, L., Glaude, E. L., Gaspard, S., & Jáuregui-Haza, U. J. (2021). In silico development of new PET radiopharmaceuticals from mTOR inhibitors. Journal of molecular graphics & modelling, 111108057. https://doi.org/10.1016/j.jmgm.2021.108057
Ferino-Pérez, Anthuan, et al. "In silico development of new PET radiopharmaceuticals from mTOR inhibitors." Journal of molecular graphics & modelling vol. 111 (2021): 108057. doi: https://doi.org/10.1016/j.jmgm.2021.108057
Ferino-Pérez A, Vélayoudom FL, Belia L, Glaude EL, Gaspard S, Jáuregui-Haza UJ. In silico development of new PET radiopharmaceuticals from mTOR inhibitors. J Mol Graph Model. 2021 Nov 24;111:108057. doi: 10.1016/j.jmgm.2021.108057. Epub 2021 Nov 24. PMID: 34847519.
Copy Download .nbib Format: NLM
In silico development of new PET radiopharmaceuticals from mTOR inhibitors.

Journal of molecular graphics & modelling

Ferino-Pérez A, Vélayoudom FL, Belia L, Glaude EL, Gaspard S, Jáuregui-Haza UJ.
PMID: 34847519
J Mol Graph Model. 2021 Nov 24;111:108057. doi: 10.1016/j.jmgm.2021.108057. Epub 2021 Nov 24.

Rapamycin (or sirolimus) is a macrolide that has shown to be useful as an immunosuppressant and that was studied in metabolic, neurological, or genetic disorders. Rapamycin is a specific natural inhibitor of the mechanistic target of rapamycin (mTOR) that...

Cite
Ferino-Pérez A, Vélayoudom FL, Belia L, et al. In silico development of new PET radiopharmaceuticals from mTOR inhibitors. J Mol Graph Model. 2021;111:108057doi: 10.1016/j.jmgm.2021.108057.
Ferino-Pérez, A., Vélayoudom, F. L., Belia, L., Glaude, E. L., Gaspard, S., & Jáuregui-Haza, U. J. (2021). In silico development of new PET radiopharmaceuticals from mTOR inhibitors. Journal of molecular graphics & modelling, 111108057. https://doi.org/10.1016/j.jmgm.2021.108057
Ferino-Pérez, Anthuan, et al. "In silico development of new PET radiopharmaceuticals from mTOR inhibitors." Journal of molecular graphics & modelling vol. 111 (2021): 108057. doi: https://doi.org/10.1016/j.jmgm.2021.108057
Ferino-Pérez A, Vélayoudom FL, Belia L, Glaude EL, Gaspard S, Jáuregui-Haza UJ. In silico development of new PET radiopharmaceuticals from mTOR inhibitors. J Mol Graph Model. 2021 Nov 24;111:108057. doi: 10.1016/j.jmgm.2021.108057. Epub 2021 Nov 24. PMID: 34847519.
Copy Download .nbib Format: NLM
In silico development of new PET radiopharmaceuticals from mTOR inhibitors.

Journal of molecular graphics & modelling

Ferino-Pérez A, Vélayoudom FL, Belia L, Glaude EL, Gaspard S, Jáuregui-Haza UJ.
PMID: 34847519
J Mol Graph Model. 2021 Nov 24;111:108057. doi: 10.1016/j.jmgm.2021.108057. Epub 2021 Nov 24.

Rapamycin (or sirolimus) is a macrolide that has shown to be useful as an immunosuppressant and that was studied in metabolic, neurological, or genetic disorders. Rapamycin is a specific natural inhibitor of the mechanistic target of rapamycin (mTOR) that...

Cite
Ferino-Pérez A, Vélayoudom FL, Belia L, et al. In silico development of new PET radiopharmaceuticals from mTOR inhibitors. J Mol Graph Model. 2021;111:108057doi: 10.1016/j.jmgm.2021.108057.
Ferino-Pérez, A., Vélayoudom, F. L., Belia, L., Glaude, E. L., Gaspard, S., & Jáuregui-Haza, U. J. (2021). In silico development of new PET radiopharmaceuticals from mTOR inhibitors. Journal of molecular graphics & modelling, 111108057. https://doi.org/10.1016/j.jmgm.2021.108057
Ferino-Pérez, Anthuan, et al. "In silico development of new PET radiopharmaceuticals from mTOR inhibitors." Journal of molecular graphics & modelling vol. 111 (2021): 108057. doi: https://doi.org/10.1016/j.jmgm.2021.108057
Ferino-Pérez A, Vélayoudom FL, Belia L, Glaude EL, Gaspard S, Jáuregui-Haza UJ. In silico development of new PET radiopharmaceuticals from mTOR inhibitors. J Mol Graph Model. 2021 Nov 24;111:108057. doi: 10.1016/j.jmgm.2021.108057. Epub 2021 Nov 24. PMID: 34847519.
Copy Download .nbib Format: NLM
In silico development of new PET radiopharmaceuticals from mTOR inhibitors.

Journal of molecular graphics & modelling

Ferino-Pérez A, Vélayoudom FL, Belia L, Glaude EL, Gaspard S, Jáuregui-Haza UJ.
PMID: 34847519
J Mol Graph Model. 2021 Nov 24;111:108057. doi: 10.1016/j.jmgm.2021.108057. Epub 2021 Nov 24.

Rapamycin (or sirolimus) is a macrolide that has shown to be useful as an immunosuppressant and that was studied in metabolic, neurological, or genetic disorders. Rapamycin is a specific natural inhibitor of the mechanistic target of rapamycin (mTOR) that...

Cite
Ferino-Pérez A, Vélayoudom FL, Belia L, et al. In silico development of new PET radiopharmaceuticals from mTOR inhibitors. J Mol Graph Model. 2021;111:108057doi: 10.1016/j.jmgm.2021.108057.
Ferino-Pérez, A., Vélayoudom, F. L., Belia, L., Glaude, E. L., Gaspard, S., & Jáuregui-Haza, U. J. (2021). In silico development of new PET radiopharmaceuticals from mTOR inhibitors. Journal of molecular graphics & modelling, 111108057. https://doi.org/10.1016/j.jmgm.2021.108057
Ferino-Pérez, Anthuan, et al. "In silico development of new PET radiopharmaceuticals from mTOR inhibitors." Journal of molecular graphics & modelling vol. 111 (2021): 108057. doi: https://doi.org/10.1016/j.jmgm.2021.108057
Ferino-Pérez A, Vélayoudom FL, Belia L, Glaude EL, Gaspard S, Jáuregui-Haza UJ. In silico development of new PET radiopharmaceuticals from mTOR inhibitors. J Mol Graph Model. 2021 Nov 24;111:108057. doi: 10.1016/j.jmgm.2021.108057. Epub 2021 Nov 24. PMID: 34847519.
Copy Download .nbib Format: NLM
In silico development of new PET radiopharmaceuticals from mTOR inhibitors.

Journal of molecular graphics & modelling

Ferino-Pérez A, Vélayoudom FL, Belia L, Glaude EL, Gaspard S, Jáuregui-Haza UJ.
PMID: 34847519
J Mol Graph Model. 2021 Nov 24;111:108057. doi: 10.1016/j.jmgm.2021.108057. Epub 2021 Nov 24.

Rapamycin (or sirolimus) is a macrolide that has shown to be useful as an immunosuppressant and that was studied in metabolic, neurological, or genetic disorders. Rapamycin is a specific natural inhibitor of the mechanistic target of rapamycin (mTOR) that...

Cite
Ferino-Pérez A, Vélayoudom FL, Belia L, et al. In silico development of new PET radiopharmaceuticals from mTOR inhibitors. J Mol Graph Model. 2021;111:108057doi: 10.1016/j.jmgm.2021.108057.
Ferino-Pérez, A., Vélayoudom, F. L., Belia, L., Glaude, E. L., Gaspard, S., & Jáuregui-Haza, U. J. (2021). In silico development of new PET radiopharmaceuticals from mTOR inhibitors. Journal of molecular graphics & modelling, 111108057. https://doi.org/10.1016/j.jmgm.2021.108057
Ferino-Pérez, Anthuan, et al. "In silico development of new PET radiopharmaceuticals from mTOR inhibitors." Journal of molecular graphics & modelling vol. 111 (2021): 108057. doi: https://doi.org/10.1016/j.jmgm.2021.108057
Ferino-Pérez A, Vélayoudom FL, Belia L, Glaude EL, Gaspard S, Jáuregui-Haza UJ. In silico development of new PET radiopharmaceuticals from mTOR inhibitors. J Mol Graph Model. 2021 Nov 24;111:108057. doi: 10.1016/j.jmgm.2021.108057. Epub 2021 Nov 24. PMID: 34847519.
Copy Download .nbib Format: NLM
In silico development of new PET radiopharmaceuticals from mTOR inhibitors.

Journal of molecular graphics & modelling

Ferino-Pérez A, Vélayoudom FL, Belia L, Glaude EL, Gaspard S, Jáuregui-Haza UJ.
PMID: 34847519
J Mol Graph Model. 2021 Nov 24;111:108057. doi: 10.1016/j.jmgm.2021.108057. Epub 2021 Nov 24.

Rapamycin (or sirolimus) is a macrolide that has shown to be useful as an immunosuppressant and that was studied in metabolic, neurological, or genetic disorders. Rapamycin is a specific natural inhibitor of the mechanistic target of rapamycin (mTOR) that...

Cite
Ferino-Pérez A, Vélayoudom FL, Belia L, et al. In silico development of new PET radiopharmaceuticals from mTOR inhibitors. J Mol Graph Model. 2021;111:108057doi: 10.1016/j.jmgm.2021.108057.
Ferino-Pérez, A., Vélayoudom, F. L., Belia, L., Glaude, E. L., Gaspard, S., & Jáuregui-Haza, U. J. (2021). In silico development of new PET radiopharmaceuticals from mTOR inhibitors. Journal of molecular graphics & modelling, 111108057. https://doi.org/10.1016/j.jmgm.2021.108057
Ferino-Pérez, Anthuan, et al. "In silico development of new PET radiopharmaceuticals from mTOR inhibitors." Journal of molecular graphics & modelling vol. 111 (2021): 108057. doi: https://doi.org/10.1016/j.jmgm.2021.108057
Ferino-Pérez A, Vélayoudom FL, Belia L, Glaude EL, Gaspard S, Jáuregui-Haza UJ. In silico development of new PET radiopharmaceuticals from mTOR inhibitors. J Mol Graph Model. 2021 Nov 24;111:108057. doi: 10.1016/j.jmgm.2021.108057. Epub 2021 Nov 24. PMID: 34847519.
Copy Download .nbib Format: NLM
In silico development of new PET radiopharmaceuticals from mTOR inhibitors.

Journal of molecular graphics & modelling

Ferino-Pérez A, Vélayoudom FL, Belia L, Glaude EL, Gaspard S, Jáuregui-Haza UJ.
PMID: 34847519
J Mol Graph Model. 2021 Nov 24;111:108057. doi: 10.1016/j.jmgm.2021.108057. Epub 2021 Nov 24.

Rapamycin (or sirolimus) is a macrolide that has shown to be useful as an immunosuppressant and that was studied in metabolic, neurological, or genetic disorders. Rapamycin is a specific natural inhibitor of the mechanistic target of rapamycin (mTOR) that...

Cite
Ferino-Pérez A, Vélayoudom FL, Belia L, et al. In silico development of new PET radiopharmaceuticals from mTOR inhibitors. J Mol Graph Model. 2021;111:108057doi: 10.1016/j.jmgm.2021.108057.
Ferino-Pérez, A., Vélayoudom, F. L., Belia, L., Glaude, E. L., Gaspard, S., & Jáuregui-Haza, U. J. (2021). In silico development of new PET radiopharmaceuticals from mTOR inhibitors. Journal of molecular graphics & modelling, 111108057. https://doi.org/10.1016/j.jmgm.2021.108057
Ferino-Pérez, Anthuan, et al. "In silico development of new PET radiopharmaceuticals from mTOR inhibitors." Journal of molecular graphics & modelling vol. 111 (2021): 108057. doi: https://doi.org/10.1016/j.jmgm.2021.108057
Ferino-Pérez A, Vélayoudom FL, Belia L, Glaude EL, Gaspard S, Jáuregui-Haza UJ. In silico development of new PET radiopharmaceuticals from mTOR inhibitors. J Mol Graph Model. 2021 Nov 24;111:108057. doi: 10.1016/j.jmgm.2021.108057. Epub 2021 Nov 24. PMID: 34847519.
Copy Download .nbib Format: NLM
Design of a prospective, longitudinal cohort of people living with type 1 diabetes exploring factors associated with the residual cardiovascular risk and other diabetes-related complications: The SFDT1 study.

Diabetes & metabolism

Riveline JP, Vergés B, Detournay B, Picard S, Benhamou PY, Bismuth E, Bordier L, Jeandidier N, Joubert M, Roussel R, Sola-Gazagnes A, Bonnefond A, Clavel S, Velayoudom FL, Beltrand J, Hanaire H, Fontaine P, Thivolet C, Servy H, Tubiana S, Lion S, Gautier JF, Larger E, Vicaut E, Sablone L, Fagherazzi G, Cosson E.
PMID: 34813929
Diabetes Metab. 2021 Nov 21;48(3):101306. doi: 10.1016/j.diabet.2021.101306. Epub 2021 Nov 21.

Type 1 diabetes mellitus (T1DM) is associated with a high risk of cardiovascular (CV) complications, even after controlling for traditional CV risk factors. Therefore, determinants of the residual increased CV morbidity and mortality remain to be discovered. This prospective...

Cite
Riveline JP, Vergés B, Detournay B, et al. Design of a prospective, longitudinal cohort of people living with type 1 diabetes exploring factors associated with the residual cardiovascular risk and other diabetes-related complications: The SFDT1 study. Diabetes Metab. 2021;48(3):101306doi: 10.1016/j.diabet.2021.101306.
Riveline, J. P., Vergés, B., Detournay, B., Picard, S., Benhamou, P. Y., Bismuth, E., Bordier, L., Jeandidier, N., Joubert, M., Roussel, R., Sola-Gazagnes, A., Bonnefond, A., Clavel, S., Velayoudom, F. L., Beltrand, J., Hanaire, H., Fontaine, P., Thivolet, C., Servy, H., Tubiana, S., Lion, S., Gautier, J. F., Larger, E., Vicaut, E., Sablone, L., Fagherazzi, G., & Cosson, E. (2021). Design of a prospective, longitudinal cohort of people living with type 1 diabetes exploring factors associated with the residual cardiovascular risk and other diabetes-related complications: The SFDT1 study. Diabetes & metabolism, 48(3), 101306. https://doi.org/10.1016/j.diabet.2021.101306
Riveline, J P, et al. "Design of a prospective, longitudinal cohort of people living with type 1 diabetes exploring factors associated with the residual cardiovascular risk and other diabetes-related complications: The SFDT1 study." Diabetes & metabolism vol. 48,3 (2021): 101306. doi: https://doi.org/10.1016/j.diabet.2021.101306
Riveline JP, Vergés B, Detournay B, Picard S, Benhamou PY, Bismuth E, Bordier L, Jeandidier N, Joubert M, Roussel R, Sola-Gazagnes A, Bonnefond A, Clavel S, Velayoudom FL, Beltrand J, Hanaire H, Fontaine P, Thivolet C, Servy H, Tubiana S, Lion S, Gautier JF, Larger E, Vicaut E, Sablone L, Fagherazzi G, Cosson E. Design of a prospective, longitudinal cohort of people living with type 1 diabetes exploring factors associated with the residual cardiovascular risk and other diabetes-related complications: The SFDT1 study. Diabetes Metab. 2021 Nov 21;48(3):101306. doi: 10.1016/j.diabet.2021.101306. Epub 2021 Nov 21. PMID: 34813929.
Copy Download .nbib Format: NLM
In silico development of new PET radiopharmaceuticals from mTOR inhibitors.

Journal of molecular graphics & modelling

Ferino-Pérez A, Vélayoudom FL, Belia L, Glaude EL, Gaspard S, Jáuregui-Haza UJ.
PMID: 34847519
J Mol Graph Model. 2021 Nov 24;111:108057. doi: 10.1016/j.jmgm.2021.108057. Epub 2021 Nov 24.

Rapamycin (or sirolimus) is a macrolide that has shown to be useful as an immunosuppressant and that was studied in metabolic, neurological, or genetic disorders. Rapamycin is a specific natural inhibitor of the mechanistic target of rapamycin (mTOR) that...

Cite
Ferino-Pérez A, Vélayoudom FL, Belia L, et al. In silico development of new PET radiopharmaceuticals from mTOR inhibitors. J Mol Graph Model. 2021;111:108057doi: 10.1016/j.jmgm.2021.108057.
Ferino-Pérez, A., Vélayoudom, F. L., Belia, L., Glaude, E. L., Gaspard, S., & Jáuregui-Haza, U. J. (2021). In silico development of new PET radiopharmaceuticals from mTOR inhibitors. Journal of molecular graphics & modelling, 111108057. https://doi.org/10.1016/j.jmgm.2021.108057
Ferino-Pérez, Anthuan, et al. "In silico development of new PET radiopharmaceuticals from mTOR inhibitors." Journal of molecular graphics & modelling vol. 111 (2021): 108057. doi: https://doi.org/10.1016/j.jmgm.2021.108057
Ferino-Pérez A, Vélayoudom FL, Belia L, Glaude EL, Gaspard S, Jáuregui-Haza UJ. In silico development of new PET radiopharmaceuticals from mTOR inhibitors. J Mol Graph Model. 2021 Nov 24;111:108057. doi: 10.1016/j.jmgm.2021.108057. Epub 2021 Nov 24. PMID: 34847519.
Copy Download .nbib Format: NLM
In silico development of new PET radiopharmaceuticals from mTOR inhibitors.

Journal of molecular graphics & modelling

Ferino-Pérez A, Vélayoudom FL, Belia L, Glaude EL, Gaspard S, Jáuregui-Haza UJ.
PMID: 34847519
J Mol Graph Model. 2021 Nov 24;111:108057. doi: 10.1016/j.jmgm.2021.108057. Epub 2021 Nov 24.

Rapamycin (or sirolimus) is a macrolide that has shown to be useful as an immunosuppressant and that was studied in metabolic, neurological, or genetic disorders. Rapamycin is a specific natural inhibitor of the mechanistic target of rapamycin (mTOR) that...

Cite
Ferino-Pérez A, Vélayoudom FL, Belia L, et al. In silico development of new PET radiopharmaceuticals from mTOR inhibitors. J Mol Graph Model. 2021;111:108057doi: 10.1016/j.jmgm.2021.108057.
Ferino-Pérez, A., Vélayoudom, F. L., Belia, L., Glaude, E. L., Gaspard, S., & Jáuregui-Haza, U. J. (2021). In silico development of new PET radiopharmaceuticals from mTOR inhibitors. Journal of molecular graphics & modelling, 111108057. https://doi.org/10.1016/j.jmgm.2021.108057
Ferino-Pérez, Anthuan, et al. "In silico development of new PET radiopharmaceuticals from mTOR inhibitors." Journal of molecular graphics & modelling vol. 111 (2021): 108057. doi: https://doi.org/10.1016/j.jmgm.2021.108057
Ferino-Pérez A, Vélayoudom FL, Belia L, Glaude EL, Gaspard S, Jáuregui-Haza UJ. In silico development of new PET radiopharmaceuticals from mTOR inhibitors. J Mol Graph Model. 2021 Nov 24;111:108057. doi: 10.1016/j.jmgm.2021.108057. Epub 2021 Nov 24. PMID: 34847519.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 18 entries